REZOLUTE INC (RZLT) Stock Fundamental Analysis
NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to RZLT. RZLT was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RZLT as it has an excellent financial health rating, but there are worries on the profitability. RZLT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year RZLT has reported negative net income.
RZLT had a negative operating cash flow in the past year.
RZLT had negative earnings in each of the past 5 years.
In the past 5 years RZLT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -63.51%, RZLT is not doing good in the industry: 61.10% of the companies in the same industry are doing better.
With a Return On Equity value of -71.43%, RZLT perfoms like the industry average, outperforming 55.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.51% | ||
| ROE | -71.43% | ||
| ROIC | N/A |
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RZLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, RZLT has more shares outstanding
The number of shares outstanding for RZLT has been increased compared to 5 years ago.
RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 6.96 indicates that RZLT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.96, RZLT belongs to the top of the industry, outperforming 82.59% of the companies in the same industry.
There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.96 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 9.30 indicates that RZLT has no problem at all paying its short term obligations.
RZLT has a Current ratio of 9.30. This is in the better half of the industry: RZLT outperforms 77.44% of its industry peers.
RZLT has a Quick Ratio of 9.30. This indicates that RZLT is financially healthy and has no problem in meeting its short term obligations.
RZLT has a Quick ratio of 9.30. This is in the better half of the industry: RZLT outperforms 77.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.3 | ||
| Quick Ratio | 9.3 |
3. Growth
3.1 Past
The earnings per share for RZLT have decreased strongly by -10.91% in the last year.
EPS 1Y (TTM)-10.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
RZLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.39% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.95%
EPS Next 2Y1.94%
EPS Next 3Y-6.77%
EPS Next 5Y22.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RZLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RZLT's earnings are expected to decrease with -6.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.94%
EPS Next 3Y-6.77%
5. Dividend
5.1 Amount
RZLT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.53
-0.1 (-2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.05%
Inst Owner Change-96.81%
Ins Owners0.86%
Ins Owner Change0.49%
Market Cap262.47M
Analysts86.25
Price Target13.37 (195.14%)
Short Float %3.07%
Short Ratio3.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.4%
Min EPS beat(2)12.17%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)1.19%
Min EPS beat(4)-32.5%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)6.68%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)12
Avg EPS beat(16)12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.85%
PT rev (3m)0.85%
EPS NQ rev (1m)4.05%
EPS NQ rev (3m)26.61%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.64 | ||
| P/tB | 2.64 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.51% | ||
| ROE | -71.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.3 | ||
| Quick Ratio | 9.3 | ||
| Altman-Z | 6.96 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.52%
EPS Next Y-21.95%
EPS Next 2Y1.94%
EPS Next 3Y-6.77%
EPS Next 5Y22.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-162.49%
OCF growth 3YN/A
OCF growth 5YN/A